Below is just my rough interpretation & rough rounded $$ figures. Any comments welcome.
I guess they have some serious R&D $$ to sprinkle some more of that 'pixie dust' you mention bigwilllly.
Approx A$55 Mil anywhere in the world pixie dust + 43.5% rebate on local pixie dust spend. The A$55 Mil has to be sprinkled by June 2025 so approx. 1 year to do the business.
They have 'pulled' an A$11Mil loan at 15% interest against the A$11 Mil rebate already - early March 2024
Interesting that there is a 50% rule - see below - i.e overseas findings cannot be more than 50% of the R&D spend. If this is the case then RCE need to spend approx. A$55 Mil in Australia before June 2025 to be able to claim the full A$55 Mil refund - i.e. A$110 Mil total spend with 50% i.e. A$55 Mil being spend overseas.
A$10Mil from this CR
Seems like a LOT will have to happen in the next year AND to get the full overseas spend of A$55 Mil they need to spend A$55 Mil - 43.5% rebate I assume ? ... so approx. A$31 Mil actual RCE $$ to be spent locally.
They had A$8.5Mil in cash at the end of last quarter SO there has to be another CR coming to get the extra approx. A$12 Mil required to be spent to be able to claim the full overseas R&D findings $$$
Hopefully that CR will be early 2025 AFTER so decent results from the upcoming future trials & an increase in SP so as not to be so dilutive.
RCE really need to get some decisive, unambiguous runs on the board to get the SP up ASAP.
https://www.bulletpoint.com.au/rd-tax-incentive-overseas-finding/
- Forums
- ASX - By Stock
- Ann: Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete
RCE
recce pharmaceuticals ltd
Add to My Watchlist
6.15%
!
30.5¢

Below is just my rough interpretation & rough rounded $$...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
30.5¢ |
Change
-0.020(6.15%) |
Mkt cap ! $87.95M |
Open | High | Low | Value | Volume |
32.5¢ | 33.0¢ | 30.5¢ | $54.63K | 174.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 22588 | 30.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.5¢ | 28921 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 22588 | 0.305 |
4 | 17833 | 0.300 |
2 | 10000 | 0.295 |
11 | 90433 | 0.290 |
2 | 135000 | 0.285 |
Price($) | Vol. | No. |
---|---|---|
0.315 | 28921 | 1 |
0.340 | 24538 | 1 |
0.350 | 30000 | 2 |
0.375 | 8002 | 1 |
0.380 | 6820 | 2 |
Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
Featured News
RCE (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online